

IN THE CLAIMS

1-10 (Canceled).

11. (Currently Amended) The method according to Claim [[10]] 20, wherein the guanylhydrazone-substituted compound is CNI-1493.

12. (Currently Amended) The method according to Claim 11, wherein ~~treatment is characterized by targeting the treating targets the~~ activation of an upstream or downstream component along the p38 MAPK signaling pathway.

13. (Previously Presented) The method according to Claim 11, wherein the disease or disorder is modulated by inhibiting signaling along a pathway within the cascade.

14. (Previously Presented) The method according to Claim 11, further comprising administering an additional therapeutic agent.

15. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an anti-viral agent.

16. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a reverse transcriptase inhibitor.

17. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is an HIV protease inhibitor.

18. (Previously Presented) The method according to Claim 14, wherein the additional therapeutic agent is a preintegration complex inhibitor.

19. (Currently Amended) The method according to Claim ~~[[10]]~~ 20, wherein the disease or disorder is modulated by inhibiting signaling along a pathway through p38 MAP kinase within the cascade.

20. (New) A method for treating HIV, comprising administering an effective HIV-treating amount of a guanyldrazone-substituted compound to a subject known to have HIV.